Mineralys Therapeutics, Valuation
| MLYS Stock | 13.11 0.59 4.71% |
At this time, the firm appears to be undervalued. Mineralys Therapeutics, secures a last-minute Real Value of USD18.24 per share. The latest price of the firm is USD13.11. Our model forecasts the value of Mineralys Therapeutics, from analyzing the firm fundamentals such as Return On Equity of -0.61, current valuation of 655.56 M, and Shares Owned By Insiders of 2.60 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Mineralys Therapeutics,'s valuation include:
Price Book 2.7538 | Enterprise Value 655.6 M | Enterprise Value Ebitda (7.41) |
Undervalued
Today
Please note that Mineralys Therapeutics,'s price fluctuation is not too volatile at this time. Calculation of the real value of Mineralys Therapeutics, is based on 3 months time horizon. Increasing Mineralys Therapeutics,'s time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Mineralys stock is determined by what a typical buyer is willing to pay for full or partial control of Mineralys Therapeutics, Common. Since Mineralys Therapeutics, is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Mineralys Stock. However, Mineralys Therapeutics,'s intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 13.11 | Real 18.24 | Target 35.75 | Hype 13.13 |
The intrinsic value of Mineralys Therapeutics,'s stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Mineralys Therapeutics,'s stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Mineralys Therapeutics, Common helps investors to forecast how Mineralys stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Mineralys Therapeutics, more accurately as focusing exclusively on Mineralys Therapeutics,'s fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Mineralys Therapeutics,'s intrinsic value based on its ongoing forecasts of Mineralys Therapeutics,'s financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Mineralys Therapeutics,'s closest peers.
Mineralys Therapeutics, Cash |
|
Mineralys Valuation Trend
Mineralys Therapeutics,'s real value is important for investors to make better decisions and a more accurate overall view of Mineralys Therapeutics,'s financial worth over time. Using both Mineralys Therapeutics,'s enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Mineralys Therapeutics, Total Value Analysis
Mineralys Therapeutics, Common is now anticipated to have valuation of 655.56 M with market capitalization of 652.47 M, debt of 10.48 M, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Mineralys Therapeutics, fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
655.56 M | 652.47 M | 10.48 M |
Mineralys Therapeutics, Asset Utilization
One of the ways to look at asset utilization of Mineralys is to check how much profit was generated for every dollar of assets it reports. Mineralys Therapeutics, Common secures a negative usage of assets of -0.39 %, losing USD0.003856 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Mineralys Therapeutics, Common shows how discouraging it operates for each dollar spent on its assets.Mineralys Therapeutics, Ownership Allocation
The majority of Mineralys Therapeutics, outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Mineralys Therapeutics, Common to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Mineralys Therapeutics,. Please pay attention to any change in the institutional holdings of Mineralys Therapeutics, as this could imply that something significant has changed or is about to change at the company.Mineralys Therapeutics, Profitability Analysis
Net Loss for the year was (71.9 M) with profit before overhead, payroll, taxes, and interest of 0.About Mineralys Therapeutics, Valuation
The stock valuation mechanism determines Mineralys Therapeutics,'s current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Mineralys Therapeutics, based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Mineralys Therapeutics,. We calculate exposure to Mineralys Therapeutics,'s market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Mineralys Therapeutics,'s related companies.Mineralys Therapeutics, Growth Indicators
Investing in growth stocks can be very risky. If the company such as Mineralys Therapeutics, does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 36.2 M | |
| Shares Float | 23.9 M |
Mineralys Therapeutics, Current Valuation Indicators
Mineralys Therapeutics,'s valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Mineralys Therapeutics,'s valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Mineralys Therapeutics,, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Mineralys Therapeutics,'s valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Mineralys Therapeutics,'s worth.Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.